James R. Berenson, MD, Inc.

February 8, 2022

Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study

On the heels of his study, Dr. James Berenson an oncologist specializing in multiple myeloma —announced his latest findings and … Article

February 7, 2022

0 Comments

IMBCR & Emory University’s Big Discovery!!!

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, … Article

February 6, 2022

0 Comments

James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center

New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative

LOS ANGELES, Nov. 11, … Article

← More posts

Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:

Monoclonal gammopathy of undetermined significance (MGUS)
Asymptomatic (smoldering/indolent) myeloma
solitary plasmacytoma of the bone
Extramedullary plasmacytoma
Light chain myeloma
Non-secretory myeloma
Osteosclerotic myeloma (POEMS syndrome)
Waldenstrom macroglobulinemia
Light chain amyloidosis
Plasma cell leukemia

Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study

IMBCR & Emory University’s Big Discovery!!!

James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center

New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative

James R. Berenson, MD

Links

Subscribe

Contact Us